Ann: Rhythm Completes Reagent Development Program, page-13

Have been watching this stock since its IPO. Pulled the trigger and started buying a month ago. And I am continuing to accumulate more at these prices.

In my experience, these biotech plays need a couple of years from IPO before they start to attract any significant interest. The problem is that most of them tend to rapidly chew through capital and blow out the capital structure. That hasn't happened here. Still well-funded, cap structure intact, ticking off the milestones and moving closer to commercialisation. The internal promotion of Glenn to CEO is a very positive move IMO. I was in contact with him last week and feel confident that he has the drive and business acumen to transition RHY from a promising startup to a commercially successful company.

I concur with others here. If RHY continues to check off its key milestones in 2019, I see this stock being several multiples of the current SP in 12-18 months.